Back to top
more

Aeglea BioTherapeutics, Inc. (AGLE)

(Delayed Data from NSDQ)

$6.96 USD

6.96
75,392

+0.24 (3.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $6.94 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Ligand (LGND) Signs Licensing Deal with xCella Biosciences

Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc.

    Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer

    Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).

      Achaogen's Plazomicin Gets Breakthrough Therapy Designation

      Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae.

        Catalyst Pharmaceuticals Focuses on Development of Firdapse

        We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX) on May 22.

          Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

          Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.

            Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA

            Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg tablets.

              Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion

              Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.

                Alexion's (ALXN) Strensiq Results Positive in Long-Term Study

                Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.

                  Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss

                  Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.

                    Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss

                    Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents.

                      Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now

                      On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).

                        Minerva (NERV) Provides Phase III Development Strategy for MIN-101

                        Minerva Neurosciences, Inc. (NERV) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101.

                          BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains

                          BioDelivery Sciences International, Inc. (BDSI) reported earnings of 58 cents per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate of 9 cents.

                            Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%

                            Alnylam Pharmaceuticals, Inc. (ALNY) shares jump a little above 16% in the last trading session.

                              Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4

                              Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.

                                Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib

                                Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.

                                  Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales

                                  Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.

                                    Geron (GERN) Q1 Loss In Line, Focus Remains on Imetelstat

                                    Geron Corporation (GERN) reported a loss of 5 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate. In the year-ago quarter.

                                      Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death

                                      Kite Pharma, Inc. (KITE) reported wider-than-expected loss in the first quarter of 2017.

                                        ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1

                                        ImmunoGen, Inc. (IMGN) reported a loss of 20 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of 36 cents and the year-ago loss of 37 cents.

                                          Juno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss

                                          Juno Therapeutics Inc. (JUNO) reported first-quarter 2017 loss of 71 cents per share (including stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 66 cents.

                                            Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus

                                            Agios Pharmaceuticals, Inc. (AGIO) posted first-quarter 2017 loss of $1.56 per share, narrower than the Zacks Consensus Estimate of a loss of $1.79 but wider than the year-ago loss of 61 cents.

                                              Zoetis (ZTS) Beats Earnings, Revenue Estimates in Q1

                                              Zoetis Inc. (ZTS) first-quarter 2017 earnings of 53 cents per share increased 10% year over year and surpassed the Zacks Consensus Estimate of 48 cents.

                                                Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y

                                                Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.

                                                  Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start

                                                  Clovis Oncology, Inc. (CLVS) reported first-quarter 2017 loss of $1.33 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.43 as well as the year-ago loss of $2.17 per share.